Llewelyn JG, et al. Sural nerve morphometry in diabetic autonomic and painful sensory ­neuropathy. A clinicopathological study. Brain. 1991;114(Pt 2):867–92.PubMedCrossRef

Malik RA, et al. Sural nerve fibre pathology in diabetic patients with mild neuropathy: relationship to pain, quantitative sensory testing and peripheral nerve electrophysiology. Acta Neuropathol. 2001;101:367–74.PubMed

Quattrini C, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148–54.PubMedCrossRef

Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29: 1294–9.PubMedCrossRef

Bursova S, et al. Expression of growth-associated protein 43 in the skin nerve fibers of patients with type 2 diabetes mellitus. J Neurol Sci. 2012;315:60–3.PubMedCrossRef

Morley GK, Mooradian AD, Levine AS, Morley JE. Mechanism of pain in diabetic peripheral neuropathy. Effect of glucose on pain perception in humans. Am J Med. 1984;77:79–82.PubMedCrossRef

Chan AW, MacFarlane IA, Bowsher D. Short term fluctuations in blood glucose concentrations do not alter pain perception in diabetic-patients with and without painful peripheral ­neuropathy. Diabetes Res. 1990;14:15–9.PubMed

Jain R, Jain S, Raison CL, Maletic V. Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators. Curr Diab Rep. 2012;11:275–84.CrossRef

Doupis J, et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009;94:2157–63.PubMedCrossRef

Bril V, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2012;76:1758–65.CrossRef

Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573–81.PubMedCrossRef

Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660–74.PubMedCrossRef

Smith HS, Argoff CE. Pharmacological treatment of diabetic neuropathic pain. Drugs. 2011;71:557–89.PubMedCrossRef

Misawa S, et al. Neuropathic pain is associated with increased nodal persistent Na(+) currents in human diabetic neuropathy. J Peripher Nerv Syst. 2009;14:279–84.PubMedCrossRef

Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21.PubMedCrossRef

Hur J, et al. The identification of gene expression profiles associated with progression of human diabetic neuropathy. Brain. 2011;134:3222–35.PubMedCrossRef

Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev. 2001;53:597–652.PubMed

Jourdan D, Ardid D, Eschalier A. Analysis of ultrasonic vocalisation does not allow chronic pain to be evaluated in rats. Pain. 2002;95:165–73.PubMedCrossRef

van Lunteren E, Moyer M, Pollarine J. Reduced amount and disrupted temporal pattern of spontaneous exercise in diabetic rats. Med Sci Sports Exerc. 2004;36:1856–62.PubMedCrossRef

Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: effects of insulin, aldose reductase inhibition and lidocaine. Pain. 1996;68:293–9.PubMedCrossRef

Brussee V, et al. Distal degenerative sensory neuropathy in a long-term type 2 diabetes rat model. Diabetes. 2008;57:1664–73.PubMedCrossRef

Hoybergs YM, Meert TF. The effect of low-dose insulin on mechanical sensitivity and ­allodynia in type I diabetes neuropathy. Neurosci Lett. 2007;417:149–54.PubMedCrossRef

Kamiya H, Murakawa Y, Zhang W, Sima AA. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev. 2005;21:448–58.PubMedCrossRef

Calcutt NA, Freshwater JD, Mizisin AP. Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia. 2004;47:718–24.PubMedCrossRef

Calcutt NA. Modeling diabetic sensory neuropathy in rats. Methods Mol Med. 2004; 99:55–65.PubMed

Bianchi R, et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci U S A. 2004;101:823–8.PubMedCrossRef

Beiswenger KK, Calcutt NA, Mizisin AP. Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett. 2008;442:267–72.PubMedCrossRef

Ahlgren SC, Levine JD. Protein kinase C inhibitors decrease hyperalgesia and C-fiber hyperexcitability in the streptozotocin-diabetic rat. J Neurophysiol. 1994;72:684–92.PubMed

de Carvalho FV, et al. Suppression of allergic inflammatory response in the skin of alloxan-diabetic rats: relationship with reduced local mast cell numbers. Int Arch Allergy Immunol. 2008;147:246–54.CrossRef

Brandner JM, Zacheja S, Houdek P, Moll I, Lobmann R. Expression of matrix metalloproteinases, cytokines, and connexins in diabetic and nondiabetic human keratinocytes before and after transplantation into an ex vivo wound-healing model. Diabetes Care. 2008;31:114–20.PubMedCrossRef

Evans L, Andrew D, Robinson P, Boissonade F, Loescher A. Increased cutaneous NGF and CGRP-labelled trkA-positive intra-epidermal nerve fibres in rat diabetic skin. Neurosci Lett. 2011;506:59–63.PubMedCrossRef

Manni L, Florenzano F, Aloe L. Electroacupuncture counteracts the development of thermal hyperalgesia and the alteration of nerve growth factor and sensory neuromodulators induced by streptozotocin in adult rats. Diabetologia. 2011;54:1900–8.PubMedCrossRef

Calcutt NA, Freshwater JD, Hauptmann N, Taylor EM, Mizisin AP. Protection of sensory function in diabetic rats by Neotrofin. Eur J Pharmacol. 2006;534:187–93.PubMedCrossRef